Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Jul 1, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.02.36a, Zolbetuximab-clzb (Vyloy®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Jul 1, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new commercial policy for Zolbetuximab-clzb (Vyloy®) has been updated, effective July 1, 2025. This is a pharmacy policy change that will impact billing and coverage for this medication.

Action Required

Action needed

By July 1, 2025: Billing team must review the full policy details at the provided URL to understand coverage requirements for Zolbetuximab-clzb (Vyloy®). Update billing system and prior authorization procedures as specified in the complete policy. Ensure providers are aware of any new requirements for prescribing this medication.

Related policy hubs

Independence Blue Cross policies Oncology Hematology